KPV

KPV (Lys-Pro-Val) is a tripeptide with a molecular weight of approximately 342.43 Da, consisting of the three C-terminal amino acid residues (positions 11-13) of alpha-melanocyte stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino acid neuropeptide derived from proopiomelanocortin (POMC) that acts primarily through melanocortin receptors. While the full alpha-MSH molecule requires the N-terminal residues for melanocortin receptor binding and pigmentation effects, the anti-inflammatory activity maps specifically to the C-terminal KPV tripeptide, which exerts its effects through a receptor-independent intracellular mechanism.

The anti-inflammatory mechanism of KPV was elucidated by Kannengiesser et al. (published in the Journal of Immunology) and involves direct nuclear translocation. KPV enters cells via peptide transporters (particularly PepT1 in intestinal epithelial cells), translocates to the nucleus, and directly inhibits NF-kB activation by preventing the phosphorylation and degradation of IkB-alpha. It also inhibits MAPK signaling by reducing phosphorylation of p38 and JNK. This dual inhibition of the two primary inflammatory signaling cascades provides broad anti-inflammatory effects without the immunosuppressive consequences of corticosteroids or biologic agents.

In preclinical models of inflammatory bowel disease, KPV has demonstrated striking efficacy. In both DSS (dextran sodium sulfate) and TNBS (trinitrobenzenesulfonic acid) colitis models, KPV reduced disease activity index scores by 60-70%, decreased histological inflammation scores, and preserved intestinal barrier integrity. The barrier-protective effects were specifically linked to maintained expression of tight junction proteins claudin-1, claudin-3, and occludin, as published by Dalmasso et al. in the Journal of Biological Chemistry (2008). These studies also showed that KPV reduced myeloperoxidase activity (a marker of neutrophil infiltration) by over 50%.

KPV demonstrates direct antimicrobial activity, particularly against Candida albicans with a minimum inhibitory concentration of 16 ug/mL. It also shows activity against Staphylococcus aureus and Escherichia coli at higher concentrations. This antimicrobial profile, combined with its anti-inflammatory and barrier-protective effects, makes KPV particularly relevant for conditions involving gut dysbiosis, fungal overgrowth, and intestinal barrier dysfunction.

The peptide can be administered via multiple routes. Subcutaneous injection provides systemic anti-inflammatory effects, while oral administration (including targeted intestinal release formulations) delivers KPV directly to the gut mucosa. The PepT1 transporter, which is highly expressed on intestinal epithelial cells, actively absorbs KPV from the intestinal lumen. Research doses range from 100-500 mcg subcutaneously or 200-1000 mcg orally. KPV's small size (just 3 amino acids, MW 342 Da) makes it exceptionally resistant to enzymatic degradation compared to larger anti-inflammatory peptides, and it maintains stability in the acidic gastric environment.

Lyophilized KPV should be stored at -20C and is stable for 24+ months. Reconstituted solutions should be refrigerated at 2-8C and used within 30 days. The tripeptide is highly water-soluble and stable across a wide pH range (3.0-8.0), which is relevant for oral formulations that must survive gastric transit. No special handling precautions are required beyond standard peptide practices. The solution should remain clear and colorless.

Preclinical safety data show an excellent tolerability profile. KPV is a fragment of an endogenous hormone (alpha-MSH) and does not bind melanocortin receptors at the concentrations used for anti-inflammatory purposes, meaning it does not cause pigmentation changes, hormonal effects, or appetite modulation. No hepatotoxicity, nephrotoxicity, or hematological adverse effects have been reported in animal studies at doses far exceeding the effective anti-inflammatory range. The receptor-independent mechanism of action reduces the risk of off-target effects associated with receptor-mediated drugs.